I n t r o d u c t i o n
Benign prostatic hyperplasia (BPH), prostatitis and carcinoma are three most common prostate lesions with BPH as the commonest lesion, affecting 210 million of the male population worldwide. 1 BPH is now considered a normal part of aging as it is present in 100% male population of age >80 years. 1 Cancer of prostate is ranked as the second most common cancer and fifth leading cause of death due to cancer in males. 2 Pathological changes that mainly affect prostate gland are prostatitis, benign prostatic hyperplasia (BPH), PIN and prostate cancer. There is an increasing incidence of prostate cancer and BPH with increasing age, however BPH is reported as the commonest lesion. 3 Histological findings of BPH are present in 20% of males at the age of 40 years, in 70% at 60 years and in 90% by the time they reach 80 years of age. 3 Peak incidence is reported in the sixth decade of life in the Pakistani population. 4 While in some other countries the peak incidence is in the ninth decade of life. 5 In addition to age, other risk factors of prostate lesions are those concerned with metabolic disorders such as diabetes, obesity, dyslipidemia and physical inactivity. 4 Digital rectal examination (DRE), Transrectal Ultrasonography, and prostate specific antigen (PSA) followed by histopathological examination are routinely used tests for the diagnosis of prostate lesions. 6 PSA is physiologically secreted in semen in high concentrations for liquefication of semen coagulum. 7 PSA is also found in human blood plasma/serum and is widely used for detection of prostate pathology since 1988. PSA levels increase in proportion with disease severity and studies have found that a steep increase in PSA level increases the likelihood of diagnosis of prostate cancer. 8, 9 Serum PSA levels <4.0 ng/ml in patients with prostate lesions are considered normal, 4-10 ng/ml are border line while >10 ng/ml are considered to have a high risk for malignancy. PSA levels are only used to diagnose lesions and histopathological examination is needed to differentiate different types of lesions.
The aim of the present study was to determine the role of serum PSA levels in differentially diagnosing the different histopathological types of prostate lesions.
M a t e r i a l a n d M e t h o d s
This retrospective study was conducted in Ibn-e-Sina Hospital Multan. Data of 2189 patients who were operated from 2007 to 2017 due to prostatic lesions were included in this analysis. Patients with inadequate biopsy specimens were excluded. Departmental and ERB approval was taken before analyzing the data. Patients with BPH, prostatitis, prostate carcinoma and prostatic intraepithelial neoplasia (PIN) were grouped according to serum PSA levels (ranging from 0 ->100 ng/ml) into five groups Serum PSA levels done before surgery were noted for each patient. Biopsy specimens were brought to the histopathology laboratory in 10% formalin solution for confirmation of the diagnosis of prostate lesions. These sections were then stained with eosin and hematoxylin stain and slides were evaluated microscopically for determination of types of lesions. Consultant histopathologist made the final diagnosis of prostate lesions.
All the data was entered in SPSS version 21. Frequencies and percentages were calculated for different histopathological findings. Association of serum PSA levels with different histopathological patterns was determined using chi-square test with P-value < 0.05 taken as a significant difference
R e s u l t s
Mean age of all patients was 62.45+10.64 years. On histopathology, BPH was diagnosed in 1676 (76.56%) patients, prostatitis in 133 (6.07%), carcinoma in 378 (17.26%) and PIN in 02 (0.09%) patients only (Table I) . On comparison of serum PSA levels with various types of histopathological lesions, almost all patients of BPH, and about 55% patients of prostatitis had PSA levels within the range of 0-10 ng/ml. About 50% patients of PIN had PSA levels in the range of 10-20 ng/ml, while more than 90% patients of prostate cancer had PSA levels >20 ng/ml (Table II) .
D i s c u s s i o n
BPH and prostate carcinoma are very common in males especially in geriatric age and results in lower urinary tract symptoms. PSA levels, DRE, and transurethral USG and biopsy investigations are routinely used tests for diagnosing prostate lesions. 10 Mean age of all patients in the present study was 62.45±10.6 years. This is in agreement with the mean age reported by multiple studies including Khant et al. (66.9 ± 9.4 years), 10 Josephine (65.5 years), 11 17, 18 All these studies report contrasting results, which are much different from our study.
Serum PSA is the most widely used tumor marker but it cannot be used alone because it has low sensitivity and specificity, especially when the PSA levels are low. Elevation of PSA level occur in conditions such as BPH, prostatitis, prostatic infarct and especially in carcinoma of prostate. In the present study, we correlated the serum PSA levels with histopathological diagnosis of prostate lesions. We found significant association of PSA with carcinoma of prostate; PSA levels were >10 ng/ml in all patients with prostate carcinoma and PIN. In our study, PSA levels <10.0 ng/ml were found in 76.65% of the patients. Murthy et al. reported normal PSA levels in more than 40% patients who underwent prostate biopsy. 19 Another study by El-imam et al. reported PSA >4 to <10.0 ng/ml in >70% of Sudanese patients. 20 Wadgaonkar et al. and Gurumurthy et al. reported findings similar to our study with significant elevation in serum PSA levels in PIN and prostate carcinoma patients. 21, 16 Serum PSA levels more than 10 ng/ml is highly indicative of prostate cancer. So, patients having PSA >10 ng/ml should be considered for surgical intervention as early as possible because of high probability of prostate carcinoma. The limitation of the present study is that we did not correlate the severity/grades of prostate cancer (Gleason scores) with serum PSA levels.
C o n c l u s i o n
In our study, benign prostatic hyperplasia was the commonest prostate lesion (76.56% of the patients) and serum PSA levels of >10 ng/ml was found in all patients with prostate carcinoma and prostatic intraepithelial neoplasia (PIN).
